Why Am I Still Sick After AL Amyloidosis Treatment?
At a Glance
Feeling sick can continue even when AL amyloidosis treatment is lowering harmful light chains because organ recovery takes months and may be incomplete. Fatigue can also come from treatment side effects, anemia, or deconditioning, while worsening symptoms need prompt medical review.
In this answer
4 sections
It can be incredibly frustrating to hear your doctor say that your treatment is working wonderfully, while you still feel exhausted, sick, and drained. This happens because recovery in AL amyloidosis involves two distinct types of responses that occur on different schedules. Your doctor is likely referring to a hematologic (blood) response, meaning the toxic light chains in your blood have dropped. However, what you are feeling physically is often tied to your organ response, which is the time it takes for your body’s tissues to slowly recover.
While it is common to experience lingering fatigue and symptoms as your organs take months to heal [1], you should never assume that severe or worsening symptoms are just delayed healing.
⚠️ When to Seek Urgent Medical Care
Worsening symptoms can sometimes signal a medical emergency, an infection, medication toxicity, or that your disease is progressing [2]. Contact your care team immediately or go to the nearest emergency room if you experience:
- New or worsening shortness of breath [3]
- Chest pain, rapid heartbeat, or new palpitations [4]
- Fainting, severe dizziness, or severe confusion [5]
- Rapid, unexplained weight gain or severe swelling in your legs [6]
- A significant drop in how much you urinate [7]
- Fever or an inability to keep fluids down [3]
Hematologic Response vs. Organ Response
To understand your recovery, it helps to look at the two different goals of AL amyloidosis treatment:
1. Hematologic (Blood) Response
The primary goal of chemotherapy or immunotherapy is to target the abnormal plasma cells in your bone marrow and stop them from producing toxic light chains [8]. Doctors measure this response primarily by looking at your serum free light chains (often checking the difference between involved and uninvolved light chains, or dFLC) [8].
- A rapid drop in these numbers—sometimes within just a few weeks—is excellent news, as it means the treatment is halting further damage [9].
- Your doctor will categorize your response as a partial response, a very good partial response (VGPR), or a complete response (CR) based on how much the light chains decrease [8]. However, even a complete hematologic response does not mean the abnormal cells are entirely eradicated, nor does it guarantee that your organs will immediately recover [10].
2. Organ Response
Even after the production of new toxic light chains drops, the amyloid proteins that have already deposited in your organs (like your heart, kidneys, or nerves) are still there, and the structural damage remains [11]. An organ response occurs when the affected organs show measurable signs of improved function over time.
- Unlike hematologic response, doctors do not measure organ response by how you feel or by assuming deposits have cleared. They look at specific clinical biomarkers [7].
- For example, they track NT-proBNP or troponin for your heart, urine protein and eGFR for your kidneys, and alkaline phosphatase for your liver [7][12].
The Variable Timeline for Organ Healing
Because hematologic and organ responses are measured differently, they occur on entirely different timelines [9]. While light chains can drop in a matter of weeks, organ recovery is a slow and sometimes incomplete process. The timing depends heavily on which organs are involved, how much damage was present before treatment began, and the depth of your hematologic response [10][9].
While everyone’s timeline is unique, studies provide median response times as general benchmarks:
- Heart: Measurable improvement in cardiac biomarkers typically takes between 3 to 9 months, though recovery can continue for years [9][1].
- Kidneys and Liver: Improvements in kidney and liver function often take 6 to 12 months, or sometimes longer [1][7].
- Nerves: If your autonomic nerves (which control blood pressure and digestion) or peripheral nerves were affected, recovery is often very gradual and can be incomplete [5].
It is important to know that in some cases, organ damage may be irreversible. Stopping the light chains prevents things from getting worse, but some organs may not fully return to their pre-disease baseline [11].
Why Fatigue and Symptoms Linger
Understanding that your organs take time to heal helps explain why you might still feel unwell. Your lingering symptoms are likely due to a combination of factors:
- Residual Organ Dysfunction: If your heart or kidneys are still working at a reduced capacity due to leftover amyloid deposits, you will naturally feel fatigued and drained [11][4].
- Treatment Side Effects: The medications used to control the disease are powerful. Therapies can cause long-lasting fatigue, low blood counts, sleep disturbances, and neuropathy [13][2].
- Anemia and Deconditioning: Low red blood cell counts (anemia) resulting from kidney disease or treatment can cause profound exhaustion [13]. Deconditioning from prolonged illness and emotional stress can also contribute significantly.
Moving Forward and Supportive Care
Hearing that your blood markers are down is excellent news, but your body has still been through a major ordeal. Focus on communicating openly with your care team about your lingering symptoms so they can help you manage them through supportive care.
Supportive care might include medication adjustments for heart failure or blood pressure, managing anemia, or working with a physical therapist to safely rebuild stamina. Always consult your medical team before changing your diet or exercise routine. Dietary changes, such as fluid, potassium, or sodium restrictions, must be highly individualized based on whether your heart or kidneys are involved.
Common questions in this guide
Why can I still feel unwell if my AL amyloidosis blood tests are better?
Does a complete response mean my organs have healed?
How long does organ recovery take after AL amyloidosis treatment?
Which tests show whether my organs are recovering?
When should I get urgent help for symptoms during treatment?
What can help with fatigue during AL amyloidosis recovery?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.My light chains have dropped, but what specific markers (like NT-proBNP or urine protein) are we tracking to measure my organ response?
- 2.What was my baseline level of organ damage before treatment, and based on that, what is a realistic expectation for my organ recovery?
- 3.What is my current hematologic response category (partial, very good partial, or complete), and how does that influence my long-term monitoring?
- 4.Are any of my current medications, or underlying issues like anemia, contributing to my prolonged fatigue?
- 5.What individualized supportive care options—such as a referral to a renal or cardiac dietitian, or specialized physical therapy—are safe and appropriate for me right now?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (13)
- 1
Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK, Brauneis D, Shelton AC, et al.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(5)):e169-e173 doi:10.1016/j.bbmt.2019.01.007.
PMID: 30639823 - 2
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.
Gertz MA, Landau H, Comenzo RL, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(10)):1097-103 doi:10.1200/JCO.2015.63.6530.
PMID: 26858336 - 3
Management of the elderly patient with AL amyloidosis.
Nuvolone M, Milani P, Palladini G, Merlini G
European journal of internal medicine 2018; (58()):48-56 doi:10.1016/j.ejim.2018.05.004.
PMID: 29801808 - 4
Amyloid Light Chain Proteins in Cardiovascular Disease: Pathogenesis and Emerging Therapies for Cardiac Amyloidosis.
Hu H, Wang Y, Xu M
Pharmaceutical research 2025; doi:10.1007/s11095-025-03965-6.
PMID: 41291170 - 5
Neuromuscular amyloidosis: Unmasking the master of disguise.
Pinto MV, Dyck PJB, Liewluck T
Muscle & nerve 2021; (64(1)):23-36 doi:10.1002/mus.27150.
PMID: 33458861 - 6
Recent advances in the management of AL Amyloidosis.
Kastritis E, Dimopoulos MA
British journal of haematology 2016; (172(2)):170-86 doi:10.1111/bjh.13805.
PMID: 26491974 - 7
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.
Muchtar E, Dispenzieri A, Leung N, et al.
Leukemia 2018; (32(10)):2240-2249 doi:10.1038/s41375-018-0060-x.
PMID: 29581546 - 8
Time to Redefine Risk-Stratification and Response Criteria in Immunoglobulin Light Chain Amyloidosis?
Jain A, Ramasamy K
Clinical lymphoma, myeloma & leukemia 2020; (20(10)):e769-e776 doi:10.1016/j.clml.2020.05.025.
PMID: 32653456 - 9
Organ responses with daratumumab therapy in previously treated AL amyloidosis.
Chung A, Kaufman GP, Sidana S, et al.
Blood advances 2020; (4(3)):458-466 doi:10.1182/bloodadvances.2019000776.
PMID: 32027745 - 10
Factors impeding organ recovery despite a deep haematological response in patients with systemic AL amyloidosis.
Staron A, Mendelson LM, Joshi T, et al.
British journal of haematology 2024; (205(6)):2268-2272 doi:10.1111/bjh.19766.
PMID: 39275899 - 11
Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response.
Grogan M, Dispenzieri A, Gertz MA
Heart (British Cardiac Society) 2017; (103(14)):1065-1072 doi:10.1136/heartjnl-2016-310704.
PMID: 28456755 - 12
Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group.
Maurer MS, Dunnmon P, Fontana M, et al.
Circulation. Heart failure 2022; (15(6)):e009038 doi:10.1161/CIRCHEARTFAILURE.121.009038.
PMID: 35331001 - 13
Immunoglobulin light-chain amyloidosis in the setting of multiple myeloma diagnosed from oral biopsy.
Pettas E, Woo SB
Journal of the American Dental Association (1939) 2026; doi:10.1016/j.adaj.2026.02.003.
PMID: 42012435
This page explains why symptoms may persist during AL amyloidosis treatment for informational purposes only and does not constitute medical advice. Contact your treatment team promptly about severe or worsening symptoms.
Get notified when new evidence is published on AL amyloidosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.